Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 366
Titolo Tipologia Data di pubblicazione Autori File
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 01 - Articolo su rivista 2025 Zappaterra, AriannaGambacorti‐Passerini, CarloCairoli, Roberto +
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 01 - Articolo su rivista 2025 Civettini, IvanZappaterra, AriannaCorti, PaolaAroldi, AndreaBiondi, AndreaCavalca, FabrizioCrippa, ValentinaCrosti, FrancescaFerrari, Giulia MariaMalighetti, FedericaMologni, LucaPiperno, AlbertoRamazzotti, DanieleScollo, ChiaraGambacorti-Passerini, Carlo +
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 01 - Articolo su rivista 2025 Manghisi, BeatriceCotilli, GiuliaTerruzzi, ElisabettaVerga, LuisaBorin, Lorenza MariaFumagalli, MonicaFerrari, Maria BeatriceMoretti, AlexPalumbo, GiovanniSteidl, CarolinaBalduzzi, AdrianaPiazza, RoccoGambacorti-Passerini, CarloAroldi, Andrea +
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 01 - Articolo su rivista 2025 Kogan, MariaAlviano, Antonio MariaCatalano, MartinaCasiraghi, AlessandraGhilardi, GiuliaRindone, GiovanniVerga, LuisaL'Imperio, VincenzoPasserini, Carlo GambacortiBonfanti, PaoloLapadula, GiuseppeCocito, FedericaSoria, Alessandro
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 02 - Intervento a convegno 2024 Fontana DMalighetti FVilla MZambon AGambacorti-Passerini CMologni L.
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 01 - Articolo su rivista 2024 Zappaterra, ARapella, AGambacorti-Passerini,CCairoli,R +
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 02 - Intervento a convegno 2024 Rindone, GGambacorti Passerini, CBonfanti, PVerga, L +
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia 01 - Articolo su rivista 2024 Fontana, DilettaGambacorti-Passerini, CarloPiazza, Rocco +
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 01 - Articolo su rivista 2024 Civettini, IvanZappaterra, AriannaGranelli, Bianca MariaRindone, GiovanniAroldi, AndreaBonfanti, StefanoColombo, FedericaFedele, MarilenaPerfetti, PaolaTerruzzi, ElisabettaGambacorti-Passerini, CarloRamazzotti, DanieleCavalca, Fabrizio +
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia 01 - Articolo su rivista 2024 Gambacorti-Passerini C.Piazza R.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 01 - Articolo su rivista 2024 Malighetti, FedericaVilla, MatteoMauri, MarioPiane, SimoneCrippa, ValentinaCrespiatico, IlariaCocito, FedericaBossi, ElisaSteidl, CarolinaCivettini, IvanScollo, ChiaraRamazzotti, DanieleGambacorti-Passerini, CarloPiazza, RoccoMologni, LucaAroldi, Andrea
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 01 - Articolo su rivista 2024 Villa, MatteoSharma, Geeta G.Malighetti, FedericaMauri, MarioCordani, NicolettaPirola, AlessandraD'Aliberti, DeborahMassimino, LucaCriscuolo, LucreziaPagani, LisaChinello, CliziaMastini, CristinaFontana, DilettaBombelli, SilviaMeneveri, RaffaellaMagni, FulvioUrso, MarioPagni, FabioRamazzotti, DanielePiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 02 - Intervento a convegno 2024 D. FontanaI. CrespiaticoC. MastiniD. D’AlibertiM. MauriCM. MercadoS. SpinelliV. CrippaE. InzoliB. ManghisiI. CivettiniD. RamazzottiV. SangiorgioM. GengottiV. BrambillaA. AroldiC. BaroneR. OrsenigoA. CorsiM. SerafiniG. CazzanigaF. PagniE. AzzoniA. SessaC. Gambacorti-PasseriniEM. ElliL. MologniRocco Piazza. +
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 01 - Articolo su rivista 2024 Antolini, LauraMantegazza, RaffaeleCairoli, RobertoGambacorti Passerini, Carlo +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 02 - Intervento a convegno 2024 Crippa, VFontana, DCivettini, IMologni, LPiazza, RGambacorti Passerini, CRamazzotti, D
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 01 - Articolo su rivista 2024 Zappaterra, AriannaCivettini, IvanPierini, SilviaGambacorti-Passerini, CarloCairoli, Roberto +
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study 01 - Articolo su rivista 2024 Gambacorti-Passerini C. +
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study 01 - Articolo su rivista 2024 Gambacorti-Passerini C. +
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases 01 - Articolo su rivista 2024 Sangiorgio V.Palasciano A.Guerra L.Pagni F.Casiraghi A.Gambacorti-Passerini C. +
Mostrati risultati da 1 a 20 di 366
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile